BDO.LiveSite.Deals.DealTypePrivate Equity & Transaction Services
BDO.LiveSite.Deals.IndustryLife Sciences
BDO.LiveSite.Deals.ClientNameCNX Therapeutics
BDO provided financial due diligence to CNX Therapeutics on their acquisition of two medicines from Sanofi SA (“Sanofi”), a global healthcare company.
CNX Therapeutics has acquired two medicines; Panacod® (paracetamol/codeine) and Propavan® (propiomazine) which are used to treat pain and insomnia respectively.
The acquisition of these products grows CNX Therapeutics’ portfolio of CNS products and expands their presence within the Nordic markets.
Acquiring these well-established products support the CNX Therapeutics’ mission to improve the lives of patients by providing access to essential medicines.
The BDO project team included: Andrew Howson, Lewis Winston and Amy Banister.
CNX Therapeutics has acquired two medicines; Panacod® (paracetamol/codeine) and Propavan® (propiomazine) which are used to treat pain and insomnia respectively.
The acquisition of these products grows CNX Therapeutics’ portfolio of CNS products and expands their presence within the Nordic markets.
Acquiring these well-established products support the CNX Therapeutics’ mission to improve the lives of patients by providing access to essential medicines.
The BDO project team included: Andrew Howson, Lewis Winston and Amy Banister.